Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model [PDF]
Journal of Veterinary Pharmacology and Therapeutics, Volume 46, Issue 1, Page 52-61, January 2023., 2023 Abstract Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the development of HCM and small molecule myosin inhibitors are an emerging class of ...
Ashley N. Sharpe +9 more
wiley +2 more sources
Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]
Archives of Medical Science: Atherosclerotic DiseasesIntroduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique +8 more
doaj +2 more sources
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial [PDF]
European Heart JournalAbstract Background and Aims The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N ...
Caroline J Coats +23 more
core +6 more sources
Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]
Frontiers in Cardiovascular MedicineIntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada +13 more
doaj +2 more sources
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy [PDF]
Journal of Cardiovascular Development and DiseaseThe management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Benedetto Ferraresi +9 more
doaj +2 more sources
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
Nature Cardiovascular ResearchAbstractHypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly ...
Hartman, James +19 more
openaire +4 more sources
Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM
Journal of Education, Health and SportBackground: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka +3 more
doaj +3 more sources
The Egyptian Heart JournalBackground A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic ...
Khadija Sarwer +6 more
doaj +2 more sources
, 2021 Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies.
Chihyuan Chuang (3742285) +17 more
core +4 more sources
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. [PDF]
Circ Heart FailBACKGROUND: Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality in children, but treatment options are limited. Aficamten, a next-in-class cardiac myosin inhibitor, directly targets the hypercontractility underlying HCM ...
Kaski JP +19 more
europepmc +2 more sources